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Introduction14.1 
The goal of this chapter is to present the WISDOM initiative, which is one of 
the main accomplishments in the use of grids for biomedical sciences 
achieved on grid infrastructures in Europe. Researchers in life sciences are 
among the most active scientifi c communities on the EGEE infrastructure. 
As a consequence, the biomedical virtual organization stands fourth in 
terms of resources consumed in 2007, with an average of 7000 jobs  submitted 
every day to the grid and more than 4 million hours of CPU consumed in 
the last 12 months. Only three experiments on the CERN Large Hadron 
Collider have used more resources. Compared to particle physics, the use of 
resources is much less centralized as about 40 different scientifi c applica-
tions are now currently deployed on EGEE. Each of them requires an amount 
of CPU which ranges from a few to a few hundred CPU years. Thanks to the 
20,000 processors available to the users of the biomedical virtual organiza-
tion, crunching factors in the hundreds are witnessed routinely. Such 
 performances were already achieved on supercomputers but at the cost of 
reservation and long delays in the access to resources. On the contrary, grid 
infrastructures are constantly open to the user communities.
Such changes in the scale of the computing resources made continuously 
available to the researchers in biomedical sciences open opportunities for 
exploring new fi elds or changing the approach to existing challenges. In 
this chapter, we would like to show the potential impact of grids in the fi eld 
of drug discovery through the example of the WISDOM initiative.
Grid-Enabled Drug Discovery14.2 
In Silico14.2.1  Drug Discovery: Requirements and Grid Added Value
The pharmaceutical R&D enterprise presents unique challenges for informa-
tion technologists and computer scientists. The diversity and  complexity of 
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the information required to arrive at well-founded decisions based on 
both scientifi c and business criteria is remarkable and well recognized in 
the industry.
Drug discovery is the process by which drugs are discovered and/or 
designed. Drug candidates are inputs to the drug development process. 
Recent progress in genomics, transcriptomics, proteomics, high through-
put screening, combinatorial chemistry, molecular biology, and pharma-
cogenomics has radically changed the traditional physiology-based 
approach to drug discovery where the organism is seen as a black box. In 
silico drug discovery contributes to increasing biological system  knowledge. 
The effi ciency gains of such an integrated knowledge system could cor-
respond to save 35% costs, or about US$300 million, and 15% time, or two 
years of development time per drug.
In silico drug discovery is one of the most promising strategies to 
speed-up the drug discovery process. It is important to know and control 
the in silico process, which is described below. Figure 14.1 shows the differ-
ent phases of a drug discovery process with their approximate duration, 
their success rate and the corresponding in silico contributions.
A target is a cellular or genetic molecule which is believed to be associ-
ated with a desired change in the behavior of diseased cells and on which 
drugs usually act. The target identifi cation and validation aims to isolate 
and select it. In silico drug discovery contributes to the target discovery by 
gene expression analysis, target function prediction and target three- 
dimensional (3D) structure prediction for postprocessing.
To identify a lead compound, a substance affecting the target selected in 
a drug-like way, two different in silico pipelines can be used which speed 
up the process and reduce costs avoiding useless in vitro tests: de novo 
design and virtual screening. De novo design builds iteratively a com-
pound from the structure of a protein active site. Virtual screening selects 
in silico the best compound from a molecule database.
FIGURE 14.1 Representation of the different phases of the drug discovery process with 
their duration, their success rate and the corresponding in silico contributions.
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Lead optimization addresses the development from the most promising 
lead compounds to a safe and effective drug. Instead of expensive and 
longer in vitro and in vivo tests, evaluation of basic chemical properties can 
be achieved by virtual screening and quantitative structure activity rela-
tionship (QSAR). QSAR is a quantitative correlation process of chemical 
structure with well-defi ned methods, such as optimization for pharma-
ceutical properties [absorption, distribution, metabolism, excretion and 
toxicity (ADMET)] or effi cacy against the target organism.
In silico drug discovery contributes to increasing biological system 
knowledge, to managing data in a collaboration space, to speeding up 
analysis and consequently increasing the low success rate of the  traditional 
“wet” approach. The effi ciency gains of such an integrated knowledge 
system could correspond to save 35% costs, or about US$300 million, and 
15% time, or two years of development time per drug.
Nevertheless, in spite of increasing levels of investment in in silico tech-
niques, there is a steady decline in the number of new molecules that enter 
clinical development and reach the market. Many factors have changed 
over the past ten years, particularly the domination of the target-based 
drug discovery paradigm, favoring screening and rational drug discovery 
programs. A new approach aims to integrate rational drug discovery with 
a strong physiology and disease focus.
Requirements14.2.1.1 
Reducing the research time and cost in the discovery stage and enhancing 
information about the leads are key priorities for pharmaceutical compa-
nies worldwide [1]. To achieve this goal, in silico drug discovery must meet 
the following requirements:
The • in silico drug discovery process includes the management of a 
large variety and quantity of scientifi c data; for example, images, 
sequences, models, and databases. Data integration is thus a chal-
lenge to increase knowledge discovery but also to ease the com-
plex workfl ow. This implies data format standardization, datafl ow 
defi nition in a distributed system, infrastructure and software 
providers for data storage, services for data and metadata regis-
tration, data manipulation, and database updates.
The • in silico drug discovery process also includes the manage-
ment of a large variety and quantity of software. Software inte-
gration is another challenge to build effi cient and complex 
workfl ows and to ease data management and data mining. 
Software can be provided in a distributed environment such as a 
Web server on the Internet. Different experts are absolutely neces-
sary to maintain and update software and workfl ows to propose 
new methods or pipelines, to use remote services, exploit outputs, 
and fi nally to propose compounds for assay. A software workfl ow 
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will assist the scientist and the decision-maker in organizing their 
work in a fl exible manner, and in delivering the information and 
knowledge to the organization.
Deploying intensive computing is a challenge for • in silico drug 
discovery. For instance, computing 1 million docking probabili-
ties or modeling 1000 compounds on one target protein requires 
in the order of a few TFlops in one day. Very large computing 
resources are also needed to describe accurately protein structure 
models by computational methods based on all-atom physics-
based force fi elds including implicit solution. Computing power 
is also required for bioinformatics resource centers where server 
access is saturated by the large number of short tasks requested 
by users.
Joining new information technologies with life sciences to enable • 
in silico drug discovery requires strong remote collaboration 
between different public and private experts when addressing 
neglected and emerging infectious diseases. It also involves strong 
sharing of resources: data and knowledge, software and workfl ow, 
and infrastructures such as computing, storage, and networks. 
The collaboration space needs experts to maintain the resources. 
Having tools and data accessible to everyone in collaboration 
requires intuitive interfaces that need to be maintained. These 
interfaces reduce the development time of new methods. They also 
help the integration of data and software from in silico drug 
 discovery but also from experimental processes.
Security is a key challenge for pharmaceutical industries but also • 
for academic institutes in most cases. Effective protection of intel-
lectual properties and sensitive information requires, for instance, 
authentication of users from different institutions, mechanisms 
for management of user accounts, and privileges and support for 
resource owners to implement and enforce access control policies.
In summary, the main requirements to develop in silico drug discovery 
are data and software integration, intensive computing deployment, 
remote collaboration and resources sharing, and, of course, security. Thus, 
there is a need for a powerful and secured environment sharing and inte-
grating remote resources such as tools, data, computing, and storage.
Grid Added Value14.2.1.2 
The grid added value in the development of in silico drug discovery for 
neglected and emerging infectious diseases has multiple dimensions:
Grids offer unprecedented opportunities for resource sharing • 
and collaboration.
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Grids open exciting perspectives for handling information fl ows.• 
Grids provide the resources to speed up the execution of time-• 
consuming software.
Grids offer unprecedented opportunities for resource sharing and 
collaboration:
The sharing of resources in a cross-organizational collaboration • 
space between the pharmaceutical industry and academic  rese arch 
institutions, and between developed and least developed countries
The creation of as a virtual laboratory for the different actors, • 
increasing cooperation and communication between partners
The mobilizing of resources routinely or in an emergency• 
The sharing of diverse, complex, large, and distributed informa-• 
tion for collaborative exploration and mutual benefi t
The use of new information technology such as large databases or • 
time-consuming software
The optimal exploitation of resources by taking advantage of spare • 
computing cycles or by maximizing the use of high-performance 
computing platforms usage
The reduction of hardware costs• 
Grids open also exciting perspectives for handling information fl ows:
The deployment of services for healthcare and research centers in • 
endemic regions
The deployment of infrastructures to collect data and improve • 
disease surveillance and monitoring
The building of knowledge space with genomics and medical • 
information (epidemiology, status of clinical tests, drug resis-
tances, etc.)
Access to relevant data, periodically updated databases and • 
publications
The federation of regional or international databases for disease • 
study and monitoring of vector control, clinical trials, and drug 
delivery
The provision of transparent and secure access to storage and • 
the archiving of large amounts of data in an automated and self- 
organized fashion
Connection, analysis and structuring of data and information in • 
a transparent mode according to predefi ned rules (science- or 
business-process-based)
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Finally, grids provide the resources to speed up the execution of time-
consuming software:
Access to large computing resources for • in silico drug discovery, 
data analysis and mathematical modeling
The application of high-performance computing to new areas• 
The production of additional or more accurate analyses• 
The facilitation of the exchange of tools and workfl ows between • 
scientists
The performance of computing intense tasks in a transparent way • 
by means of an automated job submission and distribution facility
Access to services and resources 24 hours a day• 
The running of the same job on many platforms across different • 
sites
Access to computing resources by a single effi cient path• 
Grids are unique tools for collecting and sharing information, network-
ing experts, mobilizing resources routinely or in an emergency. A grid is 
thus an appropriate environment to develop in silico drug discovery.
Grid-Enabled Virtual Screening14.2.2 
Virtual screening is about selecting in silico the best candidate drugs act-
ing on a given target protein [2]. Screening can be done in vitro but it is 
very expensive as there are now millions of chemicals that can be synthe-
sized [3]. A reliable way of in silico screening could reduce the number of 
molecules required for in vitro and then in vivo testing from a few millions 
to a few hundreds. Docking is only the fi rst step of virtual screening since 
the docking output data has to be processed further [4].
However, in silico virtual screening requires intensive computing, in the 
order of a few TFlops per day, to compute 1 million docking probabilities 
or for the molecular modeling of 1000 compounds on one target protein. 
Access to very large computing resources is therefore needed for success-
ful high throughput virtual screening [5].
The Virtual Screening Pipeline14.2.2.1 
Screening of chemical compounds against a target is an important step in 
the drug discovery process. Virtual screening is the process that screens 
the chemical compounds in silico against a target. The prerequisite to set 
up a virtual screening experiment is knowledge on the target, against 
which the screening has to be performed, and on the chemical compound 
libraries. Most of the information related to the targets is available in the 
literature, whether it is digital or paper-based.
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Docking is the method of fi rst choice for rapid in silico screening of large 
ligand databases for drug research, since it is based on a rational physical 
model. Basically, protein-compound docking is about computing the 
 binding energy of a protein target to a library of potential drugs using a 
scoring algorithm. The target is typically a protein which plays a pivotal 
role in a pathological process; for example, the biological cycles of a given 
pathogen (parasite, virus, bacteria, etc.). The goal is to identify which 
 molecules could dock on the protein active sites in order to inhibit its 
action and therefore interfere with the molecular processes essential for 
the pathogen. Libraries of compound 3D structures are made openly 
available by chemistry companies which can produce them. Many docking 
software are available either open-source or licensed.
However, there is very often a compromise between speed and accuracy 
of results (in terms of the actual binding mode as well as the calculated 
affi nity values) concerning the best scoring docking solutions. Docking 
methods usually generate a number of possible orientations of ligands in 
the binding site of the receptor, and the “correct” one (e.g. the orientation 
observed in the crystal structure) may not necessarily be ranked among 
the fi rst docking solutions. This is due to defi ciencies in orientation sam-
pling and to the approximate nature of the scoring functions. Thus, it seems 
reasonable to subject screening results to postdocking refi nement; for 
example, using molecular dynamics or similar methods that can describe 
biomolecular structure and energy in more details.
An example of workfl ow to deploy virtual screening that additionally 
includes post-docking refi nement goes through the following steps:
Step 1 Selection of the target, the chemical compound database 
and the docking software.
Step 2 Preparation. If the selected target is a X-ray crystal structure 
with a bound ligand, then it requires preparing the binding site 
of the protein by taking 6-8 Angstroms from the cocrystallized 
ligand, taking care the signifi cant amino acids for the activity are 
included in the binding site. Information on the signifi cant amino 
acids can be obtained either from the literature or from the 
Brookhaven protein database. Regarding the preparation of the 
compounds to dock, open source database providing ready to 
dock molecules are made available on internet by the companies 
selling the compounds, but both target and compound have to be 
prepared according to the needs of the software.
Step 3 Docking. Access to data analysis and visualization software 
is required at this point.
Step 4 Postdocking analysis. Results are analyzed based on the 
 docking energy score and binding mode of the compound inside 
the binding site.
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Step 5 Refi nement of docking orientations using molecular dyna-
mics and reranking of the best compounds with more accurate 
scoring functions.
Step 6 Postmolecular dynamics. analysis. Access to data analysis and 
visualization software is required at this point.
Step 7 Selection of a few hundreds of compounds for in vitro 
testing.
Figure 14.2 illustrates this workfl ow with some popular software packages.
Virtual Screening on the Grid: The WISDOM Initiative14.3 
Historical Perspective14.3.1 
The WISDOM initiative was born from discussions that took place in July 
2003 at the PharmaGrid conference in Welwyn, UK. Organized yearly 
since 2001 by the PRISM forum [6], the PharmaGrid cycle of conferences 
was aimed at steering exchanges between the leaders of the IT depart-
ments of the pharmaceutical laboratories and the developers of the grid 
technology. During the conference in Welwyn, the idea was discussed to 
identify a few topics where private and public partners could work 
together on the development and deployment of pilot projects on the grid. 
FlexX
Autodock
Amber 
Chimera 
Wet laboratory 
Millions 
Molecular docking 
Molecular dynamics 
Reranking 
MMPBSA–GBSA 
Complex 
visualization 
In vitro 
tests 
5000 
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T.igand 
2 Hydrogen 
Bonds 
Catalytic aspartic residues 
30 
FIGURE 14.2 Example of a virtual screening workfl ow (credit: A. Da Costa).
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One of the topics was in silico drug discovery for neglected diseases. 
Proposed by Martin Hofmann (SCAI, Fraunhofer Institute) and Vincent 
Breton, the idea raised interest from Manuel Peitsch who was at that time 
Global Head of Informatics and Knowledge Management at Novartis. 
After the conference, Novartis started a project focused on fi nding in silico 
new hits against dengue in partnership with University of Basel. As it was 
turning out diffi cult for other partners to contribute to this dengue pro-
ject, the idea to launch a second project on an open-grid infrastructure 
emerged. In view of previous experience, we decided to start the project 
without involving a pharmaceutical laboratory.
Discussions started in the spring of 2004 with Nicolas Jacq, who was a 
PhD student at that time at LPC Clermont-Ferrand. The fi rst decision was 
to choose a disease on which to focus our efforts. We did not have any 
a priori so we decided to ask one of our friends, the African pastor Joany 
Bazemo from Burkina-Faso, what was the worst plague in Africa. When 
asked, he did not hesitate in replying that malaria was the worst plague 
because it was killing children in hundreds of thousands. Once the 
disease was chosen, the next decision was to choose a biological target. 
This was entrusted to Vinod Kasam, a masters student at SCAI Fraunhofer, 
who studied the literature and identifi ed the family of plasmepsins as a 
new potentially promising target. Plasmepsins are involved in the degra-
dation of hemoglobin by the malaria vector, Plasmodium falciparum. 
Structures for plasmepsin II and IV were available in the Protein Data 
Base so all the ingredients were there for launching our fi rst large virtual 
screening deployment on the grid. Large-scale deployments are called 
data challenges in the EGEE jargon.
First Data Challenge on Malaria14.3.2 
Preparation14.3.2.1 
Having identifi ed the disease and the targets, there was still a lot of work 
to do in order to prepare the data challenge. On the biochemical side, three 
ingredients were required:
3D structures of targets• 
A docking software• 
A database of drug-like molecules to dock against the targets• 
We had already identifi ed the 3D structures of interest in the PDB [7] 
database.
The docking software initially selected was Autodock [8], an open-source 
algorithm developed by the Scripps Research Institute. SCAI Fraunhofer 
is known worldwide for developing one of the best docking algorithms, 
FlexX [9] but FlexX could not be deployed on multiple grid sites because it 
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is licensed software. We had planned, however, that the best compounds 
selected with Autodock would be reprocessed on Fraunhofer cluster using 
the FlexX algorithm to compare Autodock and FlexX scores.
Libraries of compound 3D structures are made available open source 
by chemistry companies which can produce them. ZINC is one of these 
open source databases of compounds [10] which is constantly growing 
and was already providing the 3D structures of more than 3.4 million 
compounds in 2005.
Tests performed in December 2004 showed that docking the whole of 
ZINC against one target using Autodock represented about 35,000 jobs of 
approximately 20 hours, corresponding to about 80 years CPU. It soon 
appeared relevant from a biochemical perspective to perform docking not 
only on one but rather on three plasmepsin II structures (1lee, 1lf2, 1lf3) 
and one plasmepsin IV structure (1ls5) obtained from the Brookhaven 
Protein Data Base. In view of this increase of the number of targets, it was 
decided to focus on a subset of ZINC, the ChemBridge database collecting 
“only” 500,000 compounds. Finally, thanks to our collaborators from SCAI 
Fraunhofer, the BioSolveIT company distributing the FlexX software made 
graciously available up to 3000 free licenses of the software for deploy-
ment on the grid. This was extremely important as we had only a limited 
experience with Autodock.
Preparation of the data challenge involved on the biochemical side a 
number of steps in relation to the preparation of the targets and the vali-
dation of the docking procedure. On the grid side, this was the fi rst time 
a biomedical application was going to require about one century of CPU 
time. At that time, only the LHC experiments had been deploying data 
challenges and the know-how for such large-scale deployments was 
shared by only a few experts. Preparation of the deployment included the 
development of an environment for job submission and output data col-
lection. This environment had to be able to handle the submission of about 
70,000 15-hour long jobs and the collection of the output data. A major 
issue was to handle job resubmission whenever a job failed for any reason, 
as the grid success rate was typically of the order of 80–85%. Large-scale 
tests were made on the French regional grid AuverGrid to validate the 
environment and to identify potential issues and bottlenecks. Other issues 
were raised by the data challenge, like the usage of licensed software on 
the grid or the need for a high throughput job submission scheme.
Based on the experience acquired during the testing phase on AuverGrid, 
the WISDOM production system (see Figure 14.3) [11] was developed in 
Perl, except the multithreaded job submission tool in Java. Two packages, 
wisdom_install and wisdom_test, were developed for installing the appli-
cation components on the resources and for testing these components, 
together with the resources and grid services.
For the user submitting jobs, the entry point was a simple command 
line tool. Its users during the data challenge were members of the 
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Biomedical Task Force, which gathers a team of engineers with recognized 
expertise in application development and deployment. This software 
environment was developed to allow the submission and monitoring of 
job sets which were called instances. The different jobs of a given instance 
have the same target input and docking software. They only differ by the 
molecules of the compound library which are docked. Tasks needed to 
submit an instance were automatically executed by the WISDOM execu-
tion system. The user, authenticated by a proxy certifi cate, had to start his 
or her instance execution following a precise submission schedule to avoid 
too much competition between the computation participants, which 
would lead to a grid overload. Once the computation had started, the 
WISDOM environment took care of monitoring jobs and registering 
results. The user only had to check regularly if the process ran correctly, 
up to the end of all the jobs belonging to the instance. The overall process 
progression could be monitored through an output fi le for follow-up mes-
sages and an error fi le in case of any problems.
For each instance, a confi guration fi le contained the instance information 
(software, target, database, parameter settings) and the grid parameters 
(number of jobs for the instance, resource brokers, computing elements, 
storage elements). A shell script and a job description language fi le were 
created for each job and used by the submission tool.
On the worker node, after the environment was confi gured, the shell 
script downloaded the database fi le from a storage element chosen by the 
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FIGURE 14.3 Design of the WISDOM production system.
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information system using the LCG API. Binaries were then called with the 
target and parameter settings transferred with the job. The compressed 
result was stored on a storage element and registered in the grid fi le cata-
log. A backup copy was also generated on another storage element. For the 
sake of simplifi cation, the most relevant metadata relative to the output 
(software, parameter settings, compounds database, etc.) were stored in 
the name of the output itself. Output, errors and accounting messages 
were transferred on the user interface.
Execution of FlexX jobs required handling fl oating licenses. Each job 
using FlexX software was contacting the Flexlm server at the beginning of 
the job and asked for a license, namely an ASCII fi le with specifi c keys 
generated for this server. Then the job was able to run without connection 
to the license server. Accessing fl oating licenses on the grid behind fi re-
walls required known IP and the opening of two specifi c ports for insti-
tutes hosting worker nodes.
Deployment14.3.2.2 
The deployment took place in July and August 2005. During this period, 
ten users launched jobs from fi ve user interfaces, monitoring the process 
with the help of the WISDOM environment and interacting with the user 
support of the EGEE project and the nodes administrators. For a total of 
80 CPU years, 72,751 jobs were launched, producing 1 TB of data (500 GB, 
doubled for the back-up). Detailed analysis of the deployment can be 
found in [11] from which Table 14.1 is extracted.
Q3
TABLE 14.1
Main Metrics from WISDOM First Data Challenge
Metrics Total FlexX Phase Autodock Phase
Cumulated number of docked compounds
 (in millions)
4127 3141 987
Effective duration 37 days 22 days 15 days
Number of docked compounds/hour 46475 59488 27417
Crunching factor 662 411 1031
Number of jobs submitted 72751 41520 31231
Number of grid computing elements used 58 56 57
Number of resource brokers used 12 12 11
Maximum number of jobs running in
 parallel on the grid
1643 1008 1643
Volume of output data 946 GB 506 GB 440 GB
Total CPU time 80 years 29.5 years 50.5 years
Effective CPU time used by successful jobs 67.2 years 24.8 years 42.4 years
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The data challenge was very useful to identify the limitations and 
 bottlenecks of the EGEE infrastructure. The WISDOM production system 
developed to submit the jobs on the grid accounted for a small fraction of 
the failures as well as the grid management system. On the other hand, the 
resource brokers were observed to signifi cantly limit the rate at which the 
jobs could be submitted. Another signifi cant source of ineffi ciency came 
from the diffi culty for the grid information system to provide all the rel-
evant information to the resource brokers when they distributed the jobs 
on the grid. As a consequence, job scheduling was a time-consuming task 
for the WISDOM users during all the data challenge due to the encoun-
tered limitations of the information system, the computing  elements, and 
the resource brokers.
Results14.3.2.3 
Postprocessing of the huge amount of data generated was a very demand-
ing task as millions of docking scores had to be compared. At the end of 
the large-scale docking deployment, the best 1000 compounds based on 
scoring were selected thanks to postprocessing ranking jobs deployed on 
the grid. They were inspected individually. Several strategies were 
employed to reduce the number of false positives. A further 100 com-
pounds were selected for postprocessing. These compounds had been 
selected based on the docking score, the binding mode of the compound 
inside the binding pocket, and the interactions of the compounds to key 
residues of the protein.
Several scaffolds were identifi ed in the 100 compounds selected for 
postprocessing. The urea, thiourea, and guanidino scaffolds were the 
most frequently observed in the top 1000 compounds. Some of the com-
pounds identifi ed were similar to already known plasmepsin inhibitors, 
like the urea analogs which were already established as micromolar 
inhibitors for plasmepsins (Walter Reed compounds) [12]. These results 
were already an indication that the overall approach was sensible and that 
large-scale docking on computational grids had the potential to identify 
new inhibitors, such as the guanidino analogs. To confi rm these results, a 
new step had to be implemented: the refi nement of the compound selec-
tion using molecular dynamics computations.
Molecular Dynamics on the Grid14.3.3 
Introduction14.3.3.1 
While docking methods have been signifi cantly improved in the last few 
years by including more thorough compound orientation searches, addi-
tional energy contributions, and/or refi ned parameters in the force fi eld, it 
is generally agreed that docking results need to be postprocessed with 
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more accurate modeling tools before biological tests are undertaken. 
Molecular dynamics (MD) [13] has great potential at this stage: fi rst, it 
enables a fl exible treatment of the compound/target complexes at room 
temperature for a given simulation time, and therefore is able to refi ne 
compound orientations by fi nding more stable complexes; second, it 
 partially solves conformation and orientation search defi ciencies which 
might arise from docking; third, it allows the reranking of molecules 
based on more accurate scoring functions.
Just at the time when the results of the fi rst WISDOM data challenge were 
being analyzed at SCAI Fraunhofer by Vinod Kasam, the BioinfoGRID proj-
ect was launched in January 2006. LPC Clermont-Ferrand contribution to 
the project focused on the deployment of MD computations on the grid.
Deployment14.3.3.2 
Work started on the identifi cation of the relevant molecular dynamics 
software and on the choice of the grid infrastructure on which to deploy 
the computations. Contacts were established with two groups at SCAI 
Fraunhofer and University of Modena which expressed interest to rerank 
the best hits coming out of the fi rst WISDOM data challenge. Both groups 
were using the Amber software for molecular modeling which raised 
again the problem of deploying a licensed software on a grid. Contacts 
were established with the institution distributing Amber regarding the 
license policy on the grid.
The outcome of the negotiation was that we were allowed to deploy 
Amber on the grid under the following conditions:
Each cluster deploying Amber had to have at least one license.• 
Grid users allowed to use Amber had to come from one of the • 
laboratories owning an Amber license.
Grid users allowed to use Amber under the conditions described • 
above could deploy their computations on all the grid clusters.
Regarding the choice of infrastructure, contacts were established with the 
EGEE biomedical virtual organization and several groups involved in 
DEISA. A clear preference for deployment on EGEE was expressed by the 
groups collaborating with us at University of Modena and SCAI Fraunhofer. 
Both had developed MD procedures which were well fi tted for running 
on clusters. As a consequence, we focused our efforts on deploying these 
procedures on EGEE.
From September 2006, we started to investigate in details the deploy-
ment of the MD procedure designed by Giulio Rastelli (University of 
Modena and Reggio Emilia) on EGEE and based on the Amber software 
package. Amber [14] is a suite of different tools that carry out molecular 
dynamics simulations. The simulations in Amber can be divided into 
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three phases and different programs of the Amber distribution are respon-
sible for performing these steps:
Preparatory phase• 
Simulatory phase• 
Analysis phase• 
Encoding these steps in separate programs has some important advan-
tages. First, it allows individual pieces to be upgraded or replaced with 
minimal impact on other parts of the program suite. Second, it allows dif-
ferent programs to be written with different coding practices: LEAP is 
written in C using X-window libraries, ptraj and antechamber are text-
based C codes, mm-pbsa is implemented in Perl, and the main simulation 
programs are coded in Fortran 90. Third, this separation often eases port-
ing to new computing platforms: only the principal simulation codes 
(sander and pmemd) need to be coded for parallel operations or need to 
know about optimized (perhaps vendor-supplied) libraries. The prepara-
tion and analysis programs are carried out on local machines on a user’s 
desktop, whereas time-consuming simulation tasks are sent to a batch 
system on a remote machine; having stable and well-defi ned fi le formats 
for these interfaces facilitates this mode of operation.
Molecular Dynamics Refi nement and Rescoring Procedure14.3.3.3 
An automated multistep procedure for the refi nement and rescoring of 
docking screening results was designed and validated at University of 
Modena in Giulio Rastelli team [15]. The workfl ow, based on the Amber 
package, is able to automatically and effi ciently refi ne docking poses, 
which sometimes may not be accurate, and rank the compounds based on 
more accurate scoring functions. The procedure requires as input a pdb 
fi le containing the structure of the protein and a mol2 fi le containing the 
coordinates of the docked ligands. The coordinates of the docked ligand 
and target structure are merged to create the complex.
The topology fi les are created using antechamber. The ligand atoms 
are described with GAFF (general Amber force-fi eld) atom types and 
AM1-BCC charges. In order to avoid the time-consuming procedure of 
charge calculation, atomic charges of the ligand are read from the origi-
nal mol2 fi le and not computed during the procedure; this choice adds 
the advantage that charge calculation of ligands can be performed only 
once, and obtained mol2 fi les used for many other target proteins. The 
ligand charges are calculated using antechamber by means of a separate 
script. Interestingly, the same set of AM1-BCC charges can also be 
exploited for automated ligand docking and MD. Missing gaff force fi eld 
parameters for the ligand are automatically assigned by parmcheck. The 
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ligand, receptor, and complex topologies are written using leap utility 
(Amber 9). Minimization, MD, and fi nal reminimization of the com-
plexes are  performed using sander with a distance-dependent dielectric 
constant e = 4r. For each of these steps, the procedure enables the user to 
set ad hoc refi nement options depending on the application. After refi ne-
ment of the complex, a pdb fi le is generated as output and the fi nal coor-
dinates of the ligand, receptor, and complex are updated and used to 
compute the binding free energy evaluation using Amber MM-PBSA 
and MM-GBSA. The free energy results (DGMM, DGsolv, and DG’bind) are 
written to an output fi le and compounds are ranked on the basis of their 
binding free energy [15].
This workfl ow was implemented in the EGEE grid using the WISDOM 
production environment designed for the large-scale docking experi-
ments to deploy the MD procedure on the grid. The wide CPU availability 
of EGEE grid allowed the submission of a large subset of best docking 
complexes to the MD refi nement and rescoring procedure despite its high 
computational demand.
The fi rst successful deployment of the MD procedure was achieved in 
December 2006 on fake data. At preparation stage, all the required input 
fi les and Amber executables were stored on the storage element (SE) of the 
grid. At execution stage, jobs lasting approximately 20 hours were submit-
ted corresponding to 50 compound subsets. Each subset with 50 compounds 
was submitted on one worker node along with the Amber executables, tar-
get structure, and the main script controlling the MD refi nement and rescor-
ing operations. After the jobs were fi nished the result fi les (structures and 
energy scores) were copied and stored on the storage element.
Following the successful test, the 5000 best compounds coming out of the 
fi rst data challenge on plasmepsin II were refi ned and reranked. Computing 
resources from the EGEE Biomed virtual organization were used exclu-
sively; 100 CPUs were used in parallel, all of them belonged to our local 
cluster at Clermont Ferrand, due to licensing issues. One single simula tion 
was consuming ~20 CPU minutes on an Intel Xeon 3.05 machine. The 
 estimated CPU time if the simulations were to be performed on one 
machine was therefore expected to be 124 days. By using EGEE infrastruc-
ture the simulation time was signifi cantly brought down to 7 days.
Results14.3.3.4 
After rescoring the 5000 best docking results by Molecular Dynamics 
with Amber and MM-PBSA and MM-GBSA, the next step was to select the 
best compounds in the perspective of in vitro tests. The starting points 
were the two ranked lists of compounds, one according to MM-PBSA and 
the other according to MM-GBSA free energies. One hundred complexes of 
each list were analyzed manually. Each complex was visualized in 3D with 
UCSF Chimera software in order to determine the molecular interactions 
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between protein and ligand in the complex. The major criteria for selec-
tion were the ligand-making interactions to the two catalytic residues of 
plasmesin II, Asp 34 and Asp214. Second, the interaction with other key 
amino acids was checked: Gly36, Val78, Gly216, Ser79. The complexes with 
no interaction with at least one of the two amino acids of the catalytic 
dyad were rejected. The complexes which were kept had at least one main 
interaction to amino acids of catalytic dyad. In total, 30 out of 200 com-
pounds were selected for in vitro tests.
In Vitro14.3.4  Tests
The 30 compounds selected for testing showed submicromolar or nano-
molar IC50 values against recombinant P. falciparum plasmepsin II, using 
the inhibition assay based on FRET substrate degradation, which is well 
documented in the literature [16,17]. In the parasite, plasmepsin II is trans-
lated as an inactive zymogen containing a 124 amino acid-long N-terminal 
prosequence that has a membrane-spanning domain. Within the food 
vacuole the prosequence is removed by a calpain-like maturase, and active 
plasmepsin II is released [18]. Plasmepsin II was expressed well from a 
pET3d construct that contained Glu124 after initiator Met, and inclusion 
body of the protein was refolded and purifi ed to near homogeneity as 
judged by SDS-PAGE. Based on molecular mass standards, recombinant 
plasmepsin II migrates at about 37 kDa.
Pepstatin A, a general inhibitor of aspartic proteases of microbial origin 
[19], was also reported to inhibited hemoglobin degradation by extracts 
of digestive vacuoles of P. falciparum [20]. In the in vitro inhibition test, the 
recombinant plasmepsin II activity without inhibitor was used as nega-
tive control and pepstatin A was used as a positive control. Pepstatin A 
showed inhibition (IC50 80  nM) against the recombinant plasmepsin II 
activity. Among 30 compounds tested, six compounds had IC50 values 
below 80  nM. These results are extremely encouraging and suggest that 
the overall approach used to select the candidates is sensible for discovery 
of new plasmepsin inhibitors. The six compounds are currently being 
evaluated for their antimalarial activities in vitro.
Second Data Challenge on Malaria14.4 
Introduction14.4.1 
With the success achieved by the fi rst data challenge both on the computa-
tion and biological sides, several scientifi c groups around the world 
 proposed targets implicated in malaria which led to the second assault on 
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malaria. The WISDOM-II project dealt with several targets, which were 
both X-ray crystal structures and homology models. Targets from  different 
classes of proteins were also being tested; reductases such as malarial 
dihydrofolate reductase (DHFR) and transferases such as GST as can be 
seen from Table 14.2. The same procedure described previously for the 
fi rst data challenge was applied for target preparation. We had again 
the privilege to be able to use the FlexX software thanks to the generous 
support of BioSolveIT.
DHFR and dihydropteroate synthase (DHPS) are two enzymes that 
belong to the folate biosynthetic pathway. The antifolates are the most 
exploited class of antimalarials, to which belong well-known molecules 
like pyrimethamine and cycloguanil. To date, the most widely used anti-
folate is a combination of pyrimethamine, a DHFR inhibitor, and sulfa-
doxin, a DHPS inhibitor. Nevertheless, their synergic action that results in 
enhanced activity is seriously compromised by drug resistance and hyper-
sensibilization. For example, drug resistance is due to point mutations of 
various amino acids in the DHFR and DHPS (P. falciparum and P. vivax) 
active sites, and severely decreases drug effi cacy. While most antimalarial 
research has been conducted on P. falciparum DHFR, there is growing inter-
est on P. vivax DHFR, a less-studied target that is getting increasingly 
important because mixed falciparum and vivax infections are increasing, 
and parasites have developed resistance to both. Therefore, there remains a 
pressing need of new molecules apt to selectively bind these targets. To 
date, six different malarial DHFR crystal structures are available in the 
Protein Data Bank. These are the structures of wild-type P. falciparum DHFR 
(PDB code 1J3I), and of its C59R + S108N (1J3J) and N51I +  C59R +  S108N + I164L 
(1J3K) highly resistant mutants. In addition, four crystal structures of 
P. vivax DHFR are available, the wild-type structure (2BL9, 2BLB) and the 
S58R + S117N resistant mutant structures (2BLA, 2BLC). Hence, we thought 
it was a great opportunity to make use of these available resources to 
develop technology-based in silico screening on these targets. We chose 
P. falciparum DHFR (wt and the highly resistant quadruple mutant) and 
P. vivax DHFR (wt and the double mutant) structures (Table 14.2).
Evolution of the Production Environment14.4.2 
Following the experience acquired during the fi rst data challenge on 
malaria and the fi rst data challenge on avian fl u [21], the WISDOM envi-
ronment was reorganized in two different and independent tasks:
The submission of the jobs• 
The follow-up of the jobs, and eventually their resubmission, as • 
well as the collection of the job status and their publication on a 
Web site
Q3
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These two processes can be started and run simultaneously, the second 
one being fed from the information provided by the fi rst one.
As seen during the deployment against avian fl u [21], we removed the 
automatic resubmission of jobs in case of a job failure, because we thought 
that the overload generated by this automatic resubmission was a major 
cause for the poor reliability we observed during the fi rst WISDOM 
deployment. Removing the automatic resubmission of jobs helped indeed 
a lot to improve overall reliability, but this induced a large amount of work 
for the users, who had to handle manual resubmissions of the instances 
after all the jobs had fi nished. The environment was further modifi ed and 
enhanced to become more a “launch and forget” system, to carry all the 
tedious tasks and relieve the users whenever possible, such as automatic 
resubmission of jobs, automatic storage of job results in a relational data-
base, automatic and real-time update of the experiment statistics and 
 status, viewable through a Web site, and so on. As a  consequence, the 
WISDOM environment was easily customized, tested and successfully 
used by the EELA [22] and EUChinaGRID [23] virtual organization.
The main objective was also to improve the fault-tolerance of the sys-
tem, in implementing, for instance, a persistent environment that can be 
stopped and restarted at any time without risking of losing important 
information. This also proved to be also very useful as it enabled the 
whole maintenance of the scripts and code and improved the interactivity 
with the user, as the user could also manage jobs in fi ne detail; for instance, 
force the cancellation and resubmission of a scheduled job. Along with 
this, we tried to minimize the cost of the environment in terms of disk 
space and CPU consumption for the user interface. While a 500 MB quota 
account was just enough to handle a single instance during the deploy-
ment on avian fl u [21], it was now enough to handle no less than 20 instances 
simultaneously. Most of the job fi les were now generated dynamically 
which allowed also the user to modify on the fl y the confi guration of the 
resource brokers and the job requirements. This way, the user was sure 
that the next submissions would take these modifi cations into account. 
Figure 14.4 describes the overall architecture of the environment and the 
deployment process:
The user is interacting with the system through the two main scripts • 
(wisdom_submit and wisdom_status) deployed on the user inter-
face. These scripts will take care automatically of job fi les genera-
tion, submission, status follow-up, and eventually resubmission.
The jobs are submitted directly to the grid workload management • 
system, and are executed on the grid computing elements. As 
soon as it is running, a job transfers all the fi les stored on the 
 storage elements via the data management system of the grid, and 
the FlexX software, which asks a fl oating license for the FlexLm 
license server, can start to process the dockings.
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During the job lifetime the status is retrieved from the user inter-• 
face and some statistics are generated and collected to a remote 
server which hosts a relational database and outputs these statis-
tics through a Web site.
Once the job is fi nished, the outputs are stored back on the grid stor-• 
age elements via the data management system and the useful dock-
ing results are inserted directly from the grid to a relational database 
where they can later be more easily queried and analyzed.
Data Challenge Deployment14.4.3 
The deployment was performed on several grid infrastructures (Auvergrid 
[24], EELA, EGEE, EUChinaGrid) and involved at least one manager to 
oversee the process on each of them. The three groups of targets (GST, 
P. vivax and P. falciparum DHFR) were docked against the whole ZINC 
database (4.3 million ligands). The database was actually cut into 2422 
chunks of 1800 ligands each. This splitting was chosen because we wanted 
to have an approximated processing time ranging from 20 to 30 hours for 
each job (one docking process takes from 40 seconds to 1 minute depend-
ing on the CPU power). The subsets had to be stored on the grid infra-
structures. They were basically copied on a storage element and registered 
on the grid fi le catalog (LFC) and were also replicated on several locations 
whenever possible to improve fault-tolerance. We defi ned a WISDOM 
instance as being a target structure docked against the whole ZINC data-
base, with a given parameter set. Table 14.3 shows the instances deployed 
on the different infrastructures.
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FIGURE 14.4 Schematic representation of the automated multistep refi nement and rescor-
ing procedure of the ligand-target complexes based on Amber. (From Luker, K.E. et al., 
Molecular and Biochemical Parasitology, 79, 1996, 71–78.)
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A total number of 32 instances were deployed, corresponding to an over-
all workload of 77,504 jobs, and up to 140 million docking operations. As 
shown in Figure 14.5, the environment included a FlexLm server that was 
providing the fl oating licenses for the FlexX commercial software. During 
the fi rst WISDOM deployment in 2005, the license server was identifi ed as 
a potential bottleneck and point of failure because we had just one server 
available at this time. For WISDOM-II, we started the deployment with 
only one server as well. Very soon, up to three servers were made available 
at the SCAI Fraunhofer institute (http://www.scai.fraunhofer.de), with 
3000 licenses available on each server. The FlexX software binaries were 
TABLE 14.3
Instances Deployed on the Different Infrastructures during the 
WISDOM-II Data Challenge
Target Structures Number of Instances Deployed
GST (A chain) 4 on EGEE
GST (B chain) 4 on EGEE
2BL9 (P. vivax wild-type DHFR) 3 on EGEE, 1 on EELA
2BLC (P. vivax double mutant DHFR) 3 on EGEE, 1 on AuverGrid
Dm_vivax (P. vivax DHFR 2BLC minimized) 4 on EGEE
Wt_vivax (P. vivax DHFR 2BL9 minimized) 4 on EGEE
1J3K (P. falciparum quadruple mutant DHFR) 4 on EGEE
1J3I (P. falciparum wild-type DHFR) 3 on EGEE, 1 on EuChinaGRID
FIGURE 14.5 Evolution of the production environment.
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stored like all the inputs on the grid storage elements and were installed on 
the fl y on each worker node at the beginning of the job.
As the average duration of a job was around 30 hours, we submitted one 
instance per day, with a delay of 30 seconds between each submission. As 
one instance was submitted in about 20 hours, the submission process 
was quite continuous during the fi rst month of deployment. The jobs were 
submitted to 15 resource brokers in a round-robin order. At the end of a 
job, the results were stored on the grid storage elements, and directly into 
a relational database.
Figure 14.6 shows the repartition of the jobs on the different grid federa-
tions. It also shows the AuverGrid, EuChinaGRID, and EELA infrastruc-
tures contribution. Each of these three infrastructures ran one single 
instance which corresponds to 3% of the total 32 instances.
Postdocking Analysis and MD Refinement14.4.4 
Analysis of the docking results was carried out on the four targets docked. 
The University of Modena took charge and analyzed results obtained on 
DHFR targets from P. vivax and P. falciparum. CSIR, in collaboration with 
LPC Clermont-Ferrand, analyzed results on GST. Two criteria were employed 
for result analysis: statistical analysis based on scoring values and analysis 
of compounds making interactions to key residues of the receptor. Based on 
these two criteria, the best compounds coming out of the docking step were 
selected and refi ned using the MD procedure described previously.
The results refi ned with MD at the University of Modena for wild-type 
P. falciparum DHFR showed that the identifi cation of novel families of anti-
malarials whose structures are not related to classical antifolates is indeed 
possible. For wild-type P. falciparum DHFR, the best 15,000 compounds 
resulting from the docking screening (FlexX) have been refi ned with 
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FIGURE 14.6 Distribution of jobs on the different grid federations.
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molecular dynamics procedure, and the molecules have been rescored 
using MM-PBSA and MM-GBSA. Hydrogen bond analyses of the 15,000 
ligands interacting at the active site revealed a signifi cant enrichment of 
hydrogen bonds with DHFR key residues Asp54, Ile14, and Ile164 (as well 
as their combination) in the fi rst ranking positions. This fi nding may vali-
date the approach, because interaction with these residues is known to be 
required for biological activity.
In perspective, MD refi nement will also be performed on the results 
obtained with the quadruple mutant DHFR structure and the results gen-
erated with P. vivax DHFRs. Once the analyses are complete, a fi nal selec-
tion of potential inhibitors will be performed and the best candidates 
will be tested in vitro at Mahidol University (Thailand) in Worachart 
Sirawaraporn’s laboratory. MD refi nement of the results obtained on GST 
has been performed in collaboration with the University of Modena and 
the results of this rescoring step are presently under analysis.
Conclusion and Perspectives14.5 
The WISDOM initiative has demonstrated how the grid can signifi cantly 
change the approach to screening which is a mandatory step on the road 
to drug discovery. In the last couple of years, a number of targets have 
been screened in silico using grid infrastructure resources. The molecules 
that have been selected through this process have shown a signifi cant 
inhibition activity in vitro and some of them are under a patenting pro-
cess. The grid added value has been clearly demonstrated by the remark-
able increase of the virtual screening throughput up to 100,000 docked 
compounds per hour using 5000 computers on the EGEE grid.
Following this success, the WISDOM initiative, started from discussions 
between Martin Hofmann and Vincent Breton at the PharmaGrid confer-
ence in Welwin City in July 2003, has turned into a collaboration which 
has seven partners today:
CNRS in Clermont-Ferrand (http://clrpcsv.in2p3.fr) with exper-• 
tise in grid technology and Web services for life sciences
SCAI Fraunhofer institute in Bonn, with expertise in bio- and • 
chemoinformatics, in text-mining technology and author of the 
FlexX docking software
University of Modena, with expertise in molecular dynamics for • 
virtual screening and drug design on malaria
CNR-ITB Institute for Biomedical Technologies in Milano, with • 
expertise in high performance and GRID computing applications 
for bioinformatics in life science
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HealthGrid (http://healthgrid.org) with expertise in grid technol-• 
ogy for life sciences and in infrastructure support
Chonnam National University with expertise in biochemistry • 
and in vitro validation of virtual screening
KISTI in Korea with expertise in grid technology• 
Beside this core group, a number of biological laboratories have expressed 
interest to propose targets or to perform in vitro tests of the best molecules 
selected in silico:
Mahidol University in Thailand• 
University of Los Andes in Venezuela• 
CSIR and University of Pretoria in South Africa• 
These very satisfactory results obtained both on the biochemical side and 
on the grid side of the project should not hide that very signifi cant prog-
ress can be achieved on both sides.
The virtual screening pipeline described in Figure 14.2 can be refi ned at 
several levels.
In terms of target preparation, it is well known that the PDB is full • 
of bugs, especially for the structures which have been down-
loaded many years ago.
In terms of ligand selection, our approach has been very naïve as • 
we have been docking all the compounds available in ZINC and 
Chembridge. Software packages exist to perform a fi rst selection 
of the ligands on physical and chemical criteria to reduce the 
number of dockings.
The availability of three-dimensional macromolecular coordinates is a 
prerequisite for many types of studies. PDB contains many anomalies 
ranging from proteins with small deviations from normal geometry, to 
structures that fi t their submitted experimental data very poorly.
Led by CMBI, a massive rerefi nement project was launched to obtain a 
better match between the experimental data and the atomic parameters 
(coordinates, B-factors) in the structure models while not compromising 
the geometric quality of the structure models [25]. The rerefi nement of such 
a vast number of structure models requires enormous amounts  of com-
puter power. The rerefi nement of 18,738 PDB fi les with 18,738 independent 
jobs requiring from 1 to 24 hours of CPU each is a very good example of a 
parallel project ideally suitable for deployment on a  computing grid.
The rerefi nements of the structure models were done on a hybrid com-
puter environment consisting of the Biomed and EMBRACE [26] virtual 
organizations on EGEE grid infrastructure as well as several clusters of 
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EMBRACE partners in Europe. Each grid job consisted of 20 proteins that 
would run for 20 hours approximately on queues of 72 hours and were 
managed using the WISDOM production environment. More than 90% of 
the total of 17 years of CPU time was fi nished in two months. The 18,738 
rerefi nements were completed in four months. The rerefi ned structure 
models are available from http://www.cmbi.ru.nl/pdb_redo/.
Selection of ligands can signifi cantly reduce the number of compounds 
docked. It can be based on toxicity or on the properties of the target bind-
ing site. We are presently investigating existing open-source software 
packages to fi lter the ligands before their docking on the grid.
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